Key result
Chimeric sodium pumps containing a gastric proton pump sequence acquire SCH 28080 sensitivity at ~14 µM.
Why the study?
The amino acid sequences of the gastric proton-potassium pump involved in recognition of the pump-specific inhibitor SCH 28080 were not identified.
The Gln(905)-Val(930) peptide of the gastric proton pump is likely involved in the interaction of the gastric proton-potassium pump with the specific inhibitor SCH 28080.
Highlights a candidate domain for selective pump inhibition; leaves open therapeutic translation pending mammalian validation.
Na(+),K(+)-ATPase is inhibited by cardiac glycosides such as ouabain, and palytoxin, which do not inhibit gastric H(+),K(+)-ATPase. Gastric H(+),K(+)-ATPase is inhibited by SCH28080, which has no effect on Na(+),K(+)-ATPase. The goal of the current study was to identify amino acid sequences of the gastric proton-potassium pump that are involved in recognition of the pump-specific inhibitor SCH 28080. A chimeric polypeptide consisting of the rat sodium pump alpha3 subunit with the peptide Gln(905)-Val(930) of the gastric proton pump alpha subunit substituted in place of the original Asn(886)-Ala(911) sequence was expressed together with the gastric beta subunit in the yeast Saccharomyces cerevisiae. Yeast cells that express this subunit combination are sensitive to palytoxin, which interacts specifically with the sodium pump, and lose intracellular K(+) ions. The palytoxin-induced K(+) efflux is inhibited by the sodium pump-specific inhibitor ouabain and also by the gastric proton pump-specific inhibitor SCH 28080. The IC(50) for SCH 28080 inhibition of palytoxin-induced K(+) efflux is 14.3 +/- 2.4 microm, which is similar to the K(i) for SCH 28080 inhibition of ATP hydrolysis by the gastric H(+),K(+)-ATPase. In contrast, palytoxin-induced K(+) efflux from cells expressing either the native alpha3 and beta1 subunits of the sodium pump or the alpha3 subunit of the sodium pump together with the beta subunit of the gastric proton pump is inhibited by ouabain but not by SCH 28080. The acquisition of SCH 28080 sensitivity by the chimera indicates that the Gln(905)-Val(930) peptide of the gastric proton pump is likely to be involved in the interactions of the gastric proton-potassium pump with SCH 28080.
No takes yet. Share an insight, caveat, or question.
Farley et al. (2001) studied this question. Chimeric polypeptide (rat sodium pump alpha3 subunit with gastric proton pump Gln(905)-Val(930) peptide) vs. Native alpha3 and beta1 subunits of the sodium pump or alpha3 subunit with beta subunit of gastric proton pump was evaluated on SCH 28080 inhibition of palytoxin-induced K+ efflux. A chimeric sodium pump containing the Gln(905)-Val(930) sequence of the gastric proton pump acquired sensitivity to the gastric proton pump-specific inhibitor SCH 28080 (IC50 14.3 µM).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: